Medtronic (NYSE:MDT) reported new clinical data from its Navablate study of bronchoscopic microwave ablation with its Emprint ablation catheter kit to treat malignant lung nodules.
“Patients with malignant lesions in the lung often have limited therapy options due to lesion locations, comorbidities and treatment side effects,” said one of the principal investigators, Kelvin Lau — consultant thoracic surgeon at St. Bartholomew’s Hospital in London — in a news release. “The results from the Navablate study explore the potential benefit of a more individualized treatment for patients and offer a new option for surgeons and physicians to provide a minimally invasive, localized treatment of malignant lesions in the lung.”
Get the full story on our sister site Medical Design & Outsourcing.